time to resumption of any hormonal therapy
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Neal D Shore, Ugo De Giorgi, Ronald F Tutrone, James L Bailen, Erik P M Roos, Ján Kliment, Gavin Marx, Lawrence I Karsh, Miguel Ramirez-Backhaus, Edward M Uchio, Stéphane Supiot, Yiyun Tang, Brad Rosbrook, Gabriel P Haas, Matt Rosales, Fabian Zohren, Jamal Tarazi, Stephen J Freedland
J Urol 215(4) 396-407
PURPOSE: Primary analysis of the phase 3 EMBARK trial reported efficacy and safety outcomes for enzalutamide monotherapy in patients with high-risk biochemical recurrence. Here, we report secondary end points for enzalutamide monotherapy vs leuprolide alone. MATERIALS AND METHODS: Patients were randomized (1:1:1) to enzalutamide plus leuprolide, leuprolide alone, or enzalutamide monotherapy. Overall survival was a key secondary end point; non-key secondary end points were time to: distant metastasis, symptomatic progression, first symptomatic skeletal event, and resumption of any hormonal therapy. Sexual health was assessed using the Quality of Life Questionnaire-Prostate 25. Time-to-event end points were summarized using Kaplan-Meier methods with nominal P values. RESULTS: Five-year probability rates (95% CI) for enzalutamide monotherapy vs leuprolide alone were: overall survival, 89.5% (85.6-92.4) vs 87.2% (83.0-90.4); time to remaining free from distant metastasis, 86.8% (82.3-90.2) vs 81.5% (76.3-85.7); symptomatic progression, 66.6% (61.2-71.4) vs 53.3% (47.6-58.6); and first symptomatic skeletal event, 95.8% (92.9-97.6) vs 91.5% (87.8-94.1). After treatment suspension, the 5-year probability rate (95% CI) of remaining free from resumption of any hormonal therapy for leuprolide alone vs enzalutamide monotherapy was 7.8% (4.4-12.3) vs 5.6% (3.3-8.8). Sexual health was better preserved in patients treated with enzalutamide monotherapy than leuprolide alone (HR 0.76; 95% CI: 0.62-0.94; P = .008). After discontinuation, most patients were subsequently treated with hormonal therapies in both groups. CONCLUSIONS: Secondary end point results support enzalutamide monotherapy as a potential option to improve efficacy and preserve sexual health vs leuprolide alone for patients with high-risk biochemical recurrence. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02319837.
1 个 Figure · 2 个 KM 面板
Figure 2. Kaplan-Meier estimates of (A) overall survival, (B) time to distant metastasis, (C) time to symptomatic progression, (D) time to resumption of any hormonal therapy after treatment suspension, and (E) time to first confirmed deterioration of sexual function (intention-to-treat population). The data cutoff was January 31, 2023. Treatment effects by HR and 95% CI were estimated by stratified Cox regression models, as described previously. Times to distant metastasis, symptomatic progression, resumption of any hormonal therapy, and confirmed deterioration of sexual activity are presented in Supplementary Table 1 ( https://www.jurology.com ). Kaplan-Meier curves were truncated when there were zero patients at risk in both groups.
Figure 2 · Panel D
Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel E
Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。